Understanding Sleep Apnea: The Meaning Of Pahi

pAHI stands for peripheral arterial tone apnea-hypopnea index. It is a system used to determine the presence and severity of sleep apnea. pAHI is measured with a plethysmographic-based finger-mounted probe and represents arterial pulsatile volume changes of the finger that are regulated by α-adrenergic innervation of the smooth muscles of the vasculature of the finger. pAHI is used to determine whether an individual has sleep apnea and how severe it is.

Explore related products

Ellie the Elephant Has a Sleep Study

$14 $14

PAT-based device determinations of AHI

PAT is a non-invasive technology that measures arterial pulsatile volume changes at the fingertip. It identifies respiratory events and, through specific signal patterns, provides two indices: AHI and Respiratory Disturbance Index (RDI). PAT devices can detect apnea events by analysing the PAT signal, pulse rate, and oximetry.

Several studies have compared the accuracy of PAT-based devices in determining AHI with polysomnography (PSG), the standard diagnostic test for sleep disordered breathing (SDB). These studies found a high correlation between the AHI values from PAT devices and PSG, indicating that PAT technology can effectively determine AHI.

One advantage of PAT-based devices is their ability to measure AHI in the home setting, providing valuable data on sleep patterns in a natural environment. This is particularly useful for patients who may not be able to undergo overnight polysomnography due to cost, accessibility, or other factors. Additionally, PAT devices can differentiate between sleep and wake states, including REM and non-REM sleep, which is clinically important for accurate diagnosis and treatment of OSA.

However, it is important to note that AHI represents an average across the night and may not capture hour-to-hour variations. Home sleep tests that calculate AHI based on total recording time may also underestimate AHI by about 15%. Therefore, it is crucial to consider other factors and symptoms when recommending treatments for OSA.

Sleep/wake detection

One common method used for sleep/wake detection is actigraphy, which involves measuring and analysing movements, typically through wrist-worn devices or finger-mounted probes. Actigraphy helps distinguish sleep from wakefulness by evaluating parameters such as activity levels, restlessness, and sleep efficiency. However, actigraphy has limitations, especially in populations with fragmented sleep or those experiencing jet lag or shift work. Its accuracy decreases with increased wakefulness, and it tends to overestimate total sleep time and sleep efficiency in these situations.

Another technique employed in sleep/wake detection is peripheral arterial tonometry (PAT). PAT-based devices measure arterial pulsatile volume changes in the finger, which are influenced by sympathetic nervous system activity. These changes reflect different sleep stages, including REM sleep, deep sleep, and light sleep. PAT can also provide information about total sleep time (TST) and oxygen desaturation levels.

In addition to actigraphy and PAT, polysomnography (PSG) is considered the gold standard diagnostic test for SDB. PSG involves monitoring various physiological parameters during sleep, including brain activity, eye movement, muscle activity, heart rhythm, and breathing patterns. It provides a comprehensive assessment of sleep quality and helps identify sleep disorders.

Accurate sleep/wake detection is essential for diagnosing and treating sleep disorders, such as obstructive sleep apnea (OSA). By understanding an individual's sleep architecture, including the duration and quality of sleep, healthcare professionals can make informed decisions about treatment options and improve patient outcomes.

Obstructive sleep apnea

OSA is often associated with excessive daytime sleepiness (EDS), and when this occurs, it is known as obstructive sleep apnea syndrome (OSAS) or obstructive sleep apnea-hypopnea syndrome (OSAHS). OSAS is underdiagnosed by primary care physicians, with an estimated 80% of Americans with the condition believed to be undiagnosed. Apnea may occur hundreds of times a night in patients with severe OSA, and it is often accompanied by wide swings in heart rate, a sharp decrease in oxygen saturation, and brief electroencephalographic (EEG) arousals. The "three S's" are the cardinal symptoms of sleep apnea: snoring, sleepiness, and a significant other's report of sleep apnea episodes.

The apnea-hypopnea index (AHI) is a diagnostic tool used to assess the severity of OSA. It measures the number of apnea and hypopnea events per hour of sleep. AHI can be determined through polysomnography, which is the standard diagnostic test for sleep-disordered breathing. However, this method is costly and inaccessible to many patients. An alternative is to use a peripheral arterial tonometry (PAT)-based device, which has been found to strongly correlate with polysomnography results.

Treatment options for OSA vary depending on the severity of the condition. Mild cases have more options, while moderate to severe OSA is typically treated with nasal continuous positive airway pressure (CPAP). Medications have generally not been a primary treatment recommendation, but the GLP-1 receptor antagonist tirzepatide has been approved for moderate-to-severe OSA in obese adults. Additionally, central nervous system (CNS) stimulants may be considered to manage excessive daytime sleepiness associated with OSA.

Sleep apnea AHI score

The Apnea-Hypopnea Index (AHI) is a system that helps determine the severity of sleep apnea. It is a valuable tool in diagnosing and assessing obstructive sleep apnea (OSA) and is one of the first things doctors look at when diagnosing the condition. The AHI score is determined by the average number of events per night, specifically the number of apneas and hypopneas during sleep. Apneas are periods when a person stops breathing, while hypopneas are instances when airflow is blocked, causing shallow breathing. The AHI is measured on a numeric scale, with scores for adults divided into three categories:

• Mild: An AHI of at least five events per hour, but fewer than 15.
• Moderate: An AHI of at least 15 events per hour, but fewer than 30.
• Severe: An AHI of 30 events or more per hour.

The AHI is calculated by adding the total amount of apneas and hypopneas during the study and dividing that number by the total sleep time. A “normal” AHI score is anything below 5 for an adult, while an AHI of 1 or more is enough to diagnose a child with OSA. An AHI score is a key part of a sleep study, which is often recommended when a patient or their partner notices symptoms such as snoring, daytime tiredness, weight gain, morning headaches, and insomnia.

Peripheral arterial tonometry

The PAT signal can be used to detect sleep/wake cycles and specific sleep stages such as REM, deep, and light sleep. It is a validated modality for diagnosing OSA and has several advantages over in-lab polysomnography (PSG), which is considered the gold standard for OSA diagnosis. PAT is home-based, relatively inexpensive, and provides faster data analysis as no manual scoring is required.

However, PAT-based devices may overestimate or underestimate the presence and severity of OSA, leading to diagnostic misclassification in approximately 30-50% of patients. Therefore, it is recommended that if PAT suggests no or mild OSA, repeat testing with PSG should be conducted.

There have been multiple studies comparing the performance of PAT-based devices with PSG in different patient populations, including Japanese patients with cardiovascular disease (CVD). These studies have found varying levels of correlation between PAT and PSG measurements, with some studies reporting a moderate correlation in total sleep time (TST) measurements, while others have found only a weak correlation for sleep staging.

In summary, peripheral arterial tonometry is a valuable tool for the diagnosis of obstructive sleep apnea, particularly in patients with an increased risk for OSA or those who cannot undergo PSG due to cost, access, or other factors. However, it is important to validate PAT findings with PSG, especially when treatment decisions depend on the diagnosis.

Frequently asked questions